Skip to main content

Advertisement

Springer Nature Link
Log in

New Anticoagulants: Anti IIa vs Anti Xa—Is One Better?

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Traditional anticoagulant drugs, including unfractionated heparin and warfarin, have several limitations. A new strategy for the design of new antithrombotic drugs is based on selective inhibition of a specific coagulation factor. These include direct thrombin inhibitors and factor Xa inhibitors. Two parenteral direct thrombin inhibitors, lepirudin and argatroban, have FDA approval for the management of heparin-induced thrombocytopenia. Ximelagatran, an oral prodrug of the direct thrombin inhibitor melagatran, has shown efficacy in the prevention and treatment of venous thromboembolism as well as stroke prevention in patients with atrial fibrillation. Fondaparinux is a synthetic pentasaccharide, which binds to antithrombin, thereby indirectly selectively inhibiting factor Xa. Fondaparinux has demonstrated its efficacy compared to low-molecular-weight heparin in randomized clinical trials and is FDA approved for the prevention and treatment of venous thromboembolism. A number of oral direct factor Xa inhibitors as well as other oral direct thrombin inhibitors are in clinical development for the prevention and treatment of thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran and warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703–1712.

    Article  CAS  PubMed  Google Scholar 

  2. Colwell CW, Berkowitz SD, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005;87:2169–2177.

    Article  PubMed  Google Scholar 

  3. Feissinger J-N, Huisman MV, Davidson BL, et al for the THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681–689.

    Google Scholar 

  4. Schulman S, Wählander K, Lundström, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713–1721.

    CAS  PubMed  Google Scholar 

  5. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs. The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;126(Suppl):265S–286S.

    Article  CAS  PubMed  Google Scholar 

  6. Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature. 1991;350(Suppl):30–33.

    CAS  PubMed  Google Scholar 

  7. Herbert JM, Petitou M, Lormeau JC, et al. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997;15:1–26.

    CAS  Google Scholar 

  8. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002;359:1715–1720.

    Article  CAS  PubMed  Google Scholar 

  9. Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721–1726.

    Article  CAS  PubMed  Google Scholar 

  10. Bauer KA, Eriksson BI, Lassen MR, et al: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305–1310.

    Article  CAS  PubMed  Google Scholar 

  11. Eriksson BI, Bauer KA, Lassen MR, et al: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298–1304.

    Article  CAS  PubMed  Google Scholar 

  12. Turpie AGG, Bauer KA, Eriksson BI, et al. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized studies. Arch Intern Med 2002;162;1833–1840.

    Article  CAS  PubMed  Google Scholar 

  13. Eriksson BI, Lassen MR. Duration of Prophylaxis against thromboembolism with fondaparinux after hip fracture surgery: A mulicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337–1342.

    CAS  PubMed  Google Scholar 

  14. Agnelli G, Bergqvist D, Cohen AT, et al., on behalf of the PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surgery 2005;92:1212–1226.

    Google Scholar 

  15. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867–873.

    PubMed  Google Scholar 

  16. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–1702.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

    Kenneth A. Bauer MD

  2. VA Boston Healthcare System, 1400 VFW Parkway, West Roxbury, MA, 02132

    Kenneth A. Bauer MD

Authors
  1. Kenneth A. Bauer MD
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Kenneth A. Bauer MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bauer, K.A. New Anticoagulants: Anti IIa vs Anti Xa—Is One Better?. J Thromb Thrombolysis 21, 67–72 (2006). https://doi.org/10.1007/s11239-006-5579-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-006-5579-4

Key Words